Anticoagulation for stroke prevention in older adults with atrial fibrillation and comorbidity: Current evidence and treatment challenges

Avi Sabbag, Xiaoxi Yao, Konstantinos C. Siontis, Peter Noseworthy

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

The burden of atrial fibrillation (AF) is projected to increase substantially over the next decade in parallel with the aging of the population. The increasing age, level of comorbidity, and polypharmacy will complicate the treatment of older adults with AF. For instance, advanced age and chronic kidney disease have been shown to increase the risk of both thromboembolism and bleeding in patients with AF. Frailty, recurrent falls and polypharmacy, while very common among elderly patients with AF, are often overlooked in the clinical decision making despite their significant interaction with oral anticoagulant (OAC) and profound impact on the patient's clinical outcomes. Such factors should be recognized, evaluated and considered in a comprehensive decision-making process. The introduction of non-vitamin K oral anticoagulants has radically changed the management of AF allowing for a more individualized selection of OAC. An understanding of the available data regarding the performance of each of the available OAC in a variety of at risk patient populations is paramount for the safe and effective management of this patient population. The aim of this review is to appraise the current evidence, point out the gaps in knowledge, and provide recommendations regarding stroke prevention in older adults with AF and comorbid conditions.

Original languageEnglish (US)
Pages (from-to)873-889
Number of pages17
JournalKorean Circulation Journal
Volume48
Issue number10
DOIs
StatePublished - Oct 1 2018

Fingerprint

Atrial Fibrillation
Comorbidity
Stroke
Anticoagulants
Polypharmacy
Therapeutics
Thromboembolism
Chronic Renal Insufficiency
Population
Decision Making
Hemorrhage

Keywords

  • Bleeding
  • Frailty
  • NOAC
  • Stroke
  • Warfarin

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Anticoagulation for stroke prevention in older adults with atrial fibrillation and comorbidity : Current evidence and treatment challenges. / Sabbag, Avi; Yao, Xiaoxi; Siontis, Konstantinos C.; Noseworthy, Peter.

In: Korean Circulation Journal, Vol. 48, No. 10, 01.10.2018, p. 873-889.

Research output: Contribution to journalReview article

@article{e8a485e43b9841dc89ea4a632ee2c7e0,
title = "Anticoagulation for stroke prevention in older adults with atrial fibrillation and comorbidity: Current evidence and treatment challenges",
abstract = "The burden of atrial fibrillation (AF) is projected to increase substantially over the next decade in parallel with the aging of the population. The increasing age, level of comorbidity, and polypharmacy will complicate the treatment of older adults with AF. For instance, advanced age and chronic kidney disease have been shown to increase the risk of both thromboembolism and bleeding in patients with AF. Frailty, recurrent falls and polypharmacy, while very common among elderly patients with AF, are often overlooked in the clinical decision making despite their significant interaction with oral anticoagulant (OAC) and profound impact on the patient's clinical outcomes. Such factors should be recognized, evaluated and considered in a comprehensive decision-making process. The introduction of non-vitamin K oral anticoagulants has radically changed the management of AF allowing for a more individualized selection of OAC. An understanding of the available data regarding the performance of each of the available OAC in a variety of at risk patient populations is paramount for the safe and effective management of this patient population. The aim of this review is to appraise the current evidence, point out the gaps in knowledge, and provide recommendations regarding stroke prevention in older adults with AF and comorbid conditions.",
keywords = "Bleeding, Frailty, NOAC, Stroke, Warfarin",
author = "Avi Sabbag and Xiaoxi Yao and Siontis, {Konstantinos C.} and Peter Noseworthy",
year = "2018",
month = "10",
day = "1",
doi = "10.4070/kcj.2018.0261",
language = "English (US)",
volume = "48",
pages = "873--889",
journal = "Korean Circulation Journal",
issn = "1738-5520",
publisher = "Korean Society of Circulation",
number = "10",

}

TY - JOUR

T1 - Anticoagulation for stroke prevention in older adults with atrial fibrillation and comorbidity

T2 - Current evidence and treatment challenges

AU - Sabbag, Avi

AU - Yao, Xiaoxi

AU - Siontis, Konstantinos C.

AU - Noseworthy, Peter

PY - 2018/10/1

Y1 - 2018/10/1

N2 - The burden of atrial fibrillation (AF) is projected to increase substantially over the next decade in parallel with the aging of the population. The increasing age, level of comorbidity, and polypharmacy will complicate the treatment of older adults with AF. For instance, advanced age and chronic kidney disease have been shown to increase the risk of both thromboembolism and bleeding in patients with AF. Frailty, recurrent falls and polypharmacy, while very common among elderly patients with AF, are often overlooked in the clinical decision making despite their significant interaction with oral anticoagulant (OAC) and profound impact on the patient's clinical outcomes. Such factors should be recognized, evaluated and considered in a comprehensive decision-making process. The introduction of non-vitamin K oral anticoagulants has radically changed the management of AF allowing for a more individualized selection of OAC. An understanding of the available data regarding the performance of each of the available OAC in a variety of at risk patient populations is paramount for the safe and effective management of this patient population. The aim of this review is to appraise the current evidence, point out the gaps in knowledge, and provide recommendations regarding stroke prevention in older adults with AF and comorbid conditions.

AB - The burden of atrial fibrillation (AF) is projected to increase substantially over the next decade in parallel with the aging of the population. The increasing age, level of comorbidity, and polypharmacy will complicate the treatment of older adults with AF. For instance, advanced age and chronic kidney disease have been shown to increase the risk of both thromboembolism and bleeding in patients with AF. Frailty, recurrent falls and polypharmacy, while very common among elderly patients with AF, are often overlooked in the clinical decision making despite their significant interaction with oral anticoagulant (OAC) and profound impact on the patient's clinical outcomes. Such factors should be recognized, evaluated and considered in a comprehensive decision-making process. The introduction of non-vitamin K oral anticoagulants has radically changed the management of AF allowing for a more individualized selection of OAC. An understanding of the available data regarding the performance of each of the available OAC in a variety of at risk patient populations is paramount for the safe and effective management of this patient population. The aim of this review is to appraise the current evidence, point out the gaps in knowledge, and provide recommendations regarding stroke prevention in older adults with AF and comorbid conditions.

KW - Bleeding

KW - Frailty

KW - NOAC

KW - Stroke

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=85053877931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053877931&partnerID=8YFLogxK

U2 - 10.4070/kcj.2018.0261

DO - 10.4070/kcj.2018.0261

M3 - Review article

AN - SCOPUS:85053877931

VL - 48

SP - 873

EP - 889

JO - Korean Circulation Journal

JF - Korean Circulation Journal

SN - 1738-5520

IS - 10

ER -